Amedisys (AMED) Competitors

Amedisys (NASDAQ:AMED) and DaVita (NYSE:DVA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.

Which has more risk & volatility, AMED or DVA?

Amedisys has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, DaVita has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Does the media refer more to AMED or DVA?

In the previous week, Amedisys had 5 more articles in the media than DaVita. MarketBeat recorded 24 mentions for Amedisys and 19 mentions for DaVita. DaVita's average media sentiment score of 1.08 beat Amedisys' score of 1.05 indicating that DaVita is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amedisys	16 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	12 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor AMED or DVA?

DaVita received 2 more outperform votes than Amedisys when rated by MarketBeat users. Likewise, 61.18% of users gave DaVita an outperform vote while only 58.63% of users gave Amedisys an outperform vote.

Company	Underperform	Outperform
Amedisys	Outperform Votes 496 58.63%	Underperform Votes 350 41.37%
DaVita	Outperform Votes 498 61.18%	Underperform Votes 316 38.82%

Do analysts rate AMED or DVA?

Amedisys currently has a consensus price target of $100.75, suggesting a potential upside of 4.95%. DaVita has a consensus price target of $166.33, suggesting a potential upside of 18.04%. Given DaVita's higher possible upside, analysts clearly believe DaVita is more favorable than Amedisys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
DaVita	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has stronger valuation and earnings, AMED or DVA?

DaVita has higher revenue and earnings than Amedisys. DaVita is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amedisys	$2.37B	1.33	-$9.75M	$2.71	35.42
DaVita	$12.82B	0.88	$936.34M	$10.74	13.12

Is AMED or DVA more profitable?

DaVita has a net margin of 7.31% compared to Amedisys' net margin of 3.57%. DaVita's return on equity of 115.48% beat Amedisys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amedisys	3.57%	12.20%	6.74%
DaVita	7.31%	115.48%	4.94%

Do insiders and institutionals have more ownership in AMED or DVA?

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 2.1% of Amedisys shares are owned by company insiders. Comparatively, 2.0% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

DaVita beats Amedisys on 10 of the 17 factors compared between the two stocks.